茲提述思派健康科技有限公司（「本公司」）日期為2022年12月12日的招股章程，內容有關（其 中包括）委任任娜女士（「任女士」）為本公司聯席公司秘書，以及香港聯合交易所有限公司 （「聯交所」）授予本公司的豁免，即本公司自2022年12月23日（本公司上市日期）起至2025 年12月22日期間毋須就任女士擔任其中一名聯席公司秘書的資格嚴格遵守聯交所證券上 市規則（「上市規則」）第3.28及8.17條的規定。 本公司董事（「董事」）會（「董事會」）欣然宣佈，聯交所已確認任女士符合上市規則第3.28 及8.17條所規定擔任本公司公司秘書的資格。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Sipai Health Technology Co., Ltd. 思派健康科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：0314） 有關公司秘書資格的更新； 聯席公司秘書辭任及 授權代表變更 有關公司秘書資格的更新 李女士 ...

Financial Performance - Total revenue for the year 2025 was RMB 2,070,984, a decrease of 54.6% compared to RMB 4,565,434 in 2024[3] - The normalized net loss for 2025 was RMB (47,571), a reduction of 62.6% from RMB (127,076) in 2024[4] - The gross profit margin improved to 15.0% in 2025 from 8.5% in 2024, despite total gross profit declining to RMB 311,325, a 19.4% decrease[3] - The company incurred a net loss of RMB 126,778 thousand for the year, significantly improved from a loss of RMB 361,832 thousand in 2024[57] - The company's loss before tax for 2025 was RMB 128,156,000, a decrease from RMB 360,641,000 in 2024, indicating a significant improvement in financial performance[87] Revenue Breakdown - The business insurance services segment generated revenue of RMB 141,579, down 26.6% from RMB 192,958 in 2024, with corporate insurance increasing by 32.0% to RMB 90,711[3] - Revenue from the commercial insurance services business decreased by 26.6% to approximately RMB 141.6 million in 2025, primarily due to the restructuring of the Huiminbao business segment[27] - Revenue from the doctor research assistance business increased by 16.3% to approximately RMB 462.3 million in 2025, driven by growing market demand[28] - Revenue from the specialty pharmacy business fell by 63.1% to approximately RMB 1.47 billion in 2025, mainly due to strategic restructuring[29] Operational Highlights - The company's enterprise insurance services achieved a managed premium of RMB 1.09 billion, a year-on-year increase of 47.8%[16] - The number of serviced enterprises reached 619, reflecting a year-on-year growth of approximately 30.0%[16] - Total membership served surpassed 2.04 million, marking a year-on-year increase of about 79.2%[16] - The company established partnerships with nearly 100 domestic leading insurance companies and signed a five-year strategic cooperation agreement with Gallagher for customized insurance solutions[17] - The company operates 70 corporate clinics, with nearly 200,000 patient visits in 2025, up from approximately 120,000 in 2024[18] Strategic Initiatives - The company aims to enhance its core capabilities in insurance brokerage services and improve service quality and scale[9] - The strategic focus includes optimizing the structure of specialty pharmacy and health insurance services to improve overall gross margin and operational efficiency[10] - The company plans to expand its service offerings in property insurance, life sciences insurance, and reinsurance to meet the growing comprehensive risk management needs of enterprises[10] - Future strategies include leveraging global best practices in insurance brokerage to become a leading comprehensive risk management expert in China[11] - The group has established three new departments: Reinsurance, Large Commercial Risks, and Life Sciences Insurance, to enhance service capabilities and risk management solutions[23] Financial Position - Cash and specific financial assets decreased by 21.8% to RMB 931,750 from RMB 1,191,944 in 2024[4] - As of December 31, 2025, the company recorded a net current asset value of approximately RMB 572.3 million, with a debt-to-asset ratio of about 43.9%, down from 47.0% in 2024[42] - The company has no outstanding bank loans or other borrowings as of December 31, 2025, and expects future cash flow from commercialized product sales[42] - Total non-current assets increased to RMB 340,345,000 in 2025 from RMB 285,165,000 in 2024, representing an increase of approximately 19.4%[59] - Current assets decreased to RMB 1,262,563,000 in 2025 from RMB 1,980,127,000 in 2024, a decline of about 36.2%[59] Cost Management - Total sales costs decreased by 57.9% to approximately RMB 1.76 billion in 2025, consistent with the revenue decline, primarily due to the strategic restructuring of the specialty pharmacy and Huiminbao business segments[30] - Sales and marketing expenses decreased by approximately 53.7% from about RMB 278.4 million in 2024 to about RMB 128.8 million in 2025, attributed to efficiency improvements in the commercial insurance services business and strategic restructuring in other segments[33] - Administrative expenses decreased by approximately 17.9% from about RMB 324.0 million in 2024 to about RMB 265.9 million in 2025, mainly due to organizational optimization and increased administrative efficiency through digitization[34] - Research and development expenses decreased by approximately 54.2% from about RMB 22.3 million in 2024 to about RMB 10.2 million in 2025, primarily due to strategic restructuring in specific business segments[35] Shareholder Information - The company has no controlling shareholder, indicating a diversified ownership structure[62] - The company did not declare or pay any dividends during the year, consistent with 2024[88] - The board did not recommend the payment of a final dividend for the year ended December 31, 2025[55] - The company has not adopted a dividend policy and plans to retain most of its available funds for business development and growth[101] Corporate Governance - The company aims to maintain high standards of corporate governance and has adopted the corporate governance code as per the Stock Exchange listing rules[99] - The board believes that the current structure, with the same individual serving as both Chairman and CEO, ensures consistent leadership and effective strategic planning[100] - The company plans to review its corporate governance practices regularly to ensure compliance and effectiveness[99] - The audit committee, along with the board and external auditors, reviewed the accounting standards and practices adopted by the group for the fiscal year ending December 31, 2025[104]

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：0314） 須予披露交易 收購目標公司100%股權 收購事項 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Sipai Health Technology Co., Ltd. 思派健康科技有限公司 董事會宣佈，於2026年3月18日（交易時段結束後），比遜醫藥（作為買方）與賣方訂立購 股協議，基本代價為人民幣354,453,690元（受本公告所載之價格調整機制約束以及受限 制股份單位授出），據此，比遜醫藥有條件同意收購善澤科技100%股權，並將間接取得 善澤科技目前持有目標公司約98.32%股權。 與購股協議同時，比遜醫藥亦與海鄰管理訂立海鄰股份轉讓協議，並有條件同意以總代 價人民幣5,546,310元收購目標公司餘下1.68%股權。 收購事項完成後，本公司無意變更目標公司的核心管理團隊或經營策略，並將全力支持 目標公司的長遠發展。 — 1 — 進行收購事項的理由及裨益 董 ...

董事會會議召開日期 思派健康科技有限公司（「本公司」）董事會（「董事會」）宣佈，本公司將於2026年3月30日（星 期一）舉行董事會會議，藉以（其中包括）批准本公司及其附屬公司截至2025年12月31日止 財政年度的年度業績公告及考慮派發末期股息（如有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Sipai Health Technology Co., Ltd. 思派健康科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：0314） 董事會主席兼執行董事 馬旭廣 香港，2026年3月18日 於本公告日期，本公司董事會包括執行董事馬旭廣先生及李繼先生；非執行董事姚磊文 先生；及獨立非執行董事樊欣先生、何海建先生及黃蓓女士。 承董事會命 思派健康科技有限公司 ...

致：香港交易及結算所有限公司 公司名稱: 思派健康科技有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00314 | 說明 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | 已發行股份總數 | | | 上月底結存 | | | 743,711,514 | 21,866,600 | | 765,578,114 | | 增加 / 減少 (-) | | | -5,252,000 | 5,252,000 | | | | 本月底結存 | | | 738,459,514 | 27,118,600 | | 765,578,114 | 足夠公眾持股量的確認(註 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Sipai Health Technology Co., Ltd. 思派健康科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：0314） 正面盈利預告 － 虧損收窄 本公告由思派健康科技有限公司（「本公司」，連同其附屬公司及併表聯屬實體統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條及香港法例第571 章證券及期貨條例第XIVA部項下的內幕消息條文（定義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，根據對 本集團截至2025年12月31日止年度（「2025財政年度」）未經審核綜合管理賬的初步評估， 以及董事會現有可得資料，本集團預計： 正常化淨虧損及淨虧損顯著收窄主要歸因於：(a)本集團核心業務（即企業保險服務業務及 醫生研究協助業務）實現強勁增長；(b)對特藥藥 ...

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has revised its list of designated securities for short selling, effective from February 10, adding 51 new stocks while removing 31 existing ones [1]. Group 1: Newly Added Designated Securities - A total of 51 stocks have been added to the designated securities list for short selling, including notable companies such as International Business Settlement (00147), Allied Group (00373), and Asia Financial (00662) [2][3]. - The complete list of newly added stocks includes various sectors, indicating a broadening of the short selling opportunities available to investors [2][3]. Group 2: Deleted Designated Securities - 31 stocks have been removed from the current designated securities list, including companies like Far East Development (00035), Sipai Health (00314), and R&F Properties (02777) [4]. - The removal of these stocks may reflect changes in market conditions or regulatory considerations impacting their eligibility for short selling [4].

Group 1 - The company, Sipai Health (00314), announced a share buyback on February 6, 2026, spending HKD 864,000 to repurchase 364,600 shares [1]

Core Viewpoint - The Hong Kong Stock Exchange announced the addition of 51 new designated securities and the deletion of 31 existing designated securities effective from February 13, 2026, which may impact trading strategies and market dynamics for investors. Group 1: New Designated Securities - A total of 51 new designated securities will be added, including notable companies such as International Business Settlement (00147), Allied Group (00373), and Ingdan (00400) [1][2][3]. - The complete list of new designated securities includes various sectors, indicating a diversification in the types of companies being recognized for short selling [1]. Group 2: Deleted Designated Securities - 31 existing designated securities will be removed from the list, including companies like Far East Consortium International (00035), Sipai Health (00314), and Gemdale Property (00535) [3][4]. - The removal of these securities may reflect changes in market conditions or company performance, which could influence investor sentiment and trading behavior [3].

Group 1 - Hong Kong Stock Exchange announced the addition of 51 new designated securities for short selling and the deletion of 31 existing designated securities, effective from February 13, 2026 [1] - Newly added designated securities include International Business Settlement (00147), Allied Group (00373), and Ingdan (00400) [1] - Deleted designated securities include Far East Consortium (00035), Sipai Health (00314), and Gemdale Property (00535) [1] Group 2 - The complete list of newly added designated securities includes stocks such as CWT International (0521), Asia Financial (0662), and China HK Power (0931) among others [2][3] - The complete list of deleted designated securities includes stocks such as Digital Domain (0547), CIFI Holdings (0884), and Sinohope Tech (1611) among others [4][5]